

On behalf of: Par Pharmaceutical, Inc.

Entered: August 3, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioner

v.

NOVARTIS AG

Patent Owner

Case IPR2016-01479

U.S. Patent No. 9,006,224

Before LORA M. GREEN, CHRISTOPHER L. CRUMBLY, and
ROBERT A. POLLOCK, *Administrative Patent Judges*.

PETITIONER'S REPLY

TABLE OF CONTENTS

I.	Introduction.....	1
II.	The Claimed Methods Would Have Been Obvious	2
A.	Dr. Ratain Qualifies as a POSA	2
B.	Clinicians Routinely Administered the Same Treatments for PNET and Carcinoid Tumors.....	4
C.	The Teachings of Oberg 2004 Are Relevant to a POSA Seeking to Develop New PNET Treatments.....	7
D.	The '224 Patent and Prior Art Group Rapamycin, Everolimus, and Temsirolimus as a Class of Anticancer Agents.....	8
E.	A POSA Would Not Have Expected PNETs “After Failure of Cytotoxic Chemotherapy” to Be “More Resistant”	10
F.	A POSA Would Have Reasonably Expected that Everolimus Would Be Therapeutically Effective in Advanced PNETs.....	13
1.	The role of mTOR inhibitors as anticancer agents, including in NETs, was not “uncertain”	13
2.	A POSA would consider preclinical models for somatostatin receptor-positive tumors as models for NETs	17
3.	Oberg 2004 and Duran provide a reasonable expectation that everolimus would be therapeutically effective in PNETs	18
III.	Novartis Has Not Established Sufficient Evidence of Secondary Indicia to Overcome the Strong Showing of Obviousness.....	22
A.	Everolimus Does Not Have Any Unexpected Results Compared to the Closest Prior Art.....	22
1.	Novartis presents no difference between use of everolimus and rapamycin or temsirolimus to treat NETs	22
2.	Novartis presents no difference between use of everolimus as monotherapy and in combination with a somatostatin	23
3.	Novartis presents no difference between use of everolimus after failure of cytotoxic chemotherapy and chemotherapy-naïve NETs.....	24
4.	FDA-approval status is not a property of everolimus.....	24

Case IPR2016-01479
U.S. Patent No. 9,006,224

B.	Everolimus Did Not Satisfy Any Long-Felt But Unmet Needs or Succeed Where Others Had Failed	25
IV.	Conclusion	25

TABLE OF AUTHORITIES

Page(s)

CASES

<i>Alcon Research, Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012)	13
<i>Allergan, Inc. v. Apotex Inc.</i> , 754 F.3d 952 (Fed. Cir. 2014)	14, 15
<i>Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc.</i> , 752 F.3d 967 (Fed. Cir. 2014)	22
<i>CSS Fitness, Inc. v. Brunswick Corp.</i> , 288 F.3d 1359 (Fed. Cir. 2002)	3
<i>Daubert v. Merrell Dow Pharm., Inc.</i> , 509 U.S. 579 (1993).....	21
<i>Genzyme Therapeutic Prods. L.P. v. Biomarin Pharm. Inc.</i> , 825 F.3d 1360 (Fed. Cir. 2016)	15
<i>In re Mouttet</i> , 686 F.3d 1322 (Fed. Cir. 2012)	8
<i>In re O'Farrell</i> , 853 F.2d 894 (Fed. Cir. 1988)	13
<i>Merck & Cie v. Gnosis SpA</i> , 808 F.3d 829 (Fed. Cir 2015)	23
<i>Merck & Co. v. Teva Pharm. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005)	12, 19
<i>Ormco Corp. v. Align Tech., Inc.</i> , 463 F.3d 1299 (Fed. Cir. 2006)	24
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007)	13

Case IPR2016-01479
U.S. Patent No. 9,006,224

PharmaStem Therapeutics, Inc. v. ViaCell, Inc.,
491 F.3d 1342 (Fed. Cir. 2007) 9, 10

Phillips v. AWH Corp.,
415 F.3d 1303 (Fed. Cir. 2005)3

SEB S.A. v. Montgomery Ward & Co.,
594 F.3d 1360 (Fed. Cir. 2010)3

Smith & Nephew, Inc. v. Rea,
721 F.3d 1371 (Fed. Cir. 2013)8

Toro Co. v. MTD Prods. Inc.,
IPR2016-00219, Paper 39 (P.T.A.B May 10, 2017)3

OTHER AUTHORITIES

M.P.E.P. § 2107.03(IV) (2015).....20

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.